Phase 2 N=55 Supplementation With Cholecalciferol in Dialysis Patients
Chronic Kidney Disease
Primary: Change From Baseline in Interleukin-6 at 12 Weeks. — 9.0; 8.1; 9.6; 4.6 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=300 Multisite Controlled Trial of Cocaine Vaccine
Cocaine Dependence
Primary: Cocaine Abstinence During Weeks 9 to 16 Inclusive — 21; 30 participants
Phase 1 N=12 The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093
Epilepsy
Primary: Maximum Observed Plasma Concentration (Cmax) — 11302; 12799 ng/mL
Phase 3 N=619 Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85 — -0.030; 0.092; 0.081 Liters — p=<0.001
N/A N=96 Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Traumatic Brain Injury
Primary: Time ICP >20 — 1.7; .9 Hours
N/A N=50 Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)
Breast Cancer
Primary: Patients With All Positive Margins Correctly Identified With the Device — 5 Patients w/ all positives identified
N/A N=80 Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
Ankylosing Spondylitis
Primary: Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Baseline — 30.18; 49.09; 53.06; 63.29 Percentage of impairment
Phase 3 N=36 Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age
Sedation
Primary: Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion — 7.1; 7.1; 25 percentage of subjects
Phase 4 N=139 Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT
IV Contrast Dosing
Primary: Difference in Enhancement of the Liver and Blood Vessels Over Time, Measured in Hounsfield Units (HU) — 116; 124; 121; 120 Hounsfield units (HU)
N/A N=104 Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones
Urolithiasis · Urinary Lithiasis · Kidney Calculi
Primary: Stone Clearance — 76 participants
Phase 1 N=9 Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)
Plaque Psoriasis
Primary: Number of Participants With an Adverse Event of Erythema in Part I of the Study — 0; 0 Participants
N/A N=97 Traumatic Brain Injury (TBI) Screening Instruments
Brain Injury
Primary: Responses From the TBI Clinical Reminder — 61; 88 percentage of participants
Phase 3 N=71 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
Hemophilia A
Primary: Occurrence of FVIII Inhibitor Development — 0; 0; 0; 0 percentage of participants
Phase 3 N=16 A Study Investigating Treatment Factor X in People With Factor X Deficiency
Factor X Deficiency
Primary: FX:C Incremental Recovery — 2.07 IU/dL per IU/kg
Phase 4 N=226 Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department
Hypertensive Urgency
Primary: Percentage of Subjects Achieving a Pre-defined Target Systolic Blood Pressure (BP) Within 30 Minutes. — 91.7; 82.5 percentage of participants — p=0.04